Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31460580 | 0.84 | IDO1 (0.32) | EGFRIDO1TDO2 | |
| SCHEMBL856951 | 0.75 | DHFR (0.34) | — | |
| SCHEMBL29970215 | 0.73 | EGFR (0.40) | EGFRIDO1TDO2 | |
| SCHEMBL23208890 | 0.73 | EGFR (0.40) | EGFRIDO1TDO2 | |
| SCHEMBL26711263 | 0.72 | LPL (0.36) | EGFR | |
| SCHEMBL28212908 | 0.71 | BCL6 (0.41) | — | |
| SCHEMBL21851857 | 0.71 | LPL (0.35) | — | |
| SCHEMBL18985489 | 0.71 | LPL (0.35) | — | |
| SCHEMBL1344397 | 0.70 | KDR (0.43) | EGFRIDO1TDO2 | |
| SCHEMBL26921291 | 0.70 | LPL (0.31) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4522610-A1 | GCN2 INHIBITORR | IP2IPO Innovations Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | EGFR 2433/4885IDO1 3601/4885TDO2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.